The study, which enrolled 35 Japanese patients, evaluated the percent change from baseline in the 24-hour urine protein-to-creatinine ratio
Fenebrutinib targets cells in the immune system known as B cells and microglia
Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
The ALLEGORY study demonstrated statistically significant improvements in key measures, including British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response
ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia
Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
Importantly, the combination of giredestrant and everolimus was well tolerated
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Subscribe To Our Newsletter & Stay Updated
